Minerva Surgical Inc (NASDAQ:UTRS) was the recipient of a large decline in short interest in the month of January. As of January 15th, there was short interest totalling 59,500 shares, a decline of 68.1% from the December 31st total of 186,300 shares. Based on an average daily volume of 148,600 shares, the short-interest ratio is presently 0.4 days. Currently, 0.6% of the company’s shares are short sold.
Shares of UTRS stock opened at $4.42 on Friday. The stock’s 50-day moving average is $5.57. Minerva Surgical has a 1-year low of $4.28 and a 1-year high of $10.37.
Minerva Surgical (NASDAQ:UTRS) last announced its earnings results on Wednesday, December 1st. The company reported ($1.15) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.71). The business had revenue of $12.51 million for the quarter, compared to the consensus estimate of $12.23 million. As a group, equities analysts forecast that Minerva Surgical will post -2.7 EPS for the current year.
A number of analysts recently issued reports on the stock. JPMorgan Chase & Co. assumed coverage on shares of Minerva Surgical in a report on Tuesday, November 16th. They set an “overweight” rating and a $14.00 price target on the stock. Piper Sandler started coverage on shares of Minerva Surgical in a research report on Tuesday, November 16th. They issued an “overweight” rating and a $17.00 target price for the company. SVB Leerink reduced their target price on shares of Minerva Surgical from $17.00 to $12.00 and set an “outperform” rating for the company in a research report on Friday, December 3rd. Finally, UBS Group began coverage on shares of Minerva Surgical in a research report on Tuesday, November 16th. They issued a “buy” rating and a $15.00 target price for the company.
In other news, CEO David M. Clapper purchased 25,000 shares of the company’s stock in a transaction that occurred on Monday, December 13th. The stock was purchased at an average cost of $4.94 per share, with a total value of $123,500.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.
Minerva Surgical Company Profile
Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. Minerva Surgical is based in SANTA CLARA, Calif.
Featured Article: Trading Penny Stocks
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Minerva Surgical, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Minerva Surgical wasn’t on the list.
While Minerva Surgical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.